



ASX Announcement

7 May 2019

ShareRoot appoints Dr Julian Chick as Chairman

- Mr Harvey Kaplan steps down, completing the stabilization of the company
- Dr Julian Chick is a recognised and respected health technology leader with extensive capital raising and deal development experience
- Appointment establishes ShareRoot's strategy in digital health

Shareroot Limited (ASX: SRO) ("ShareRoot" or "the Company") today announced the appointment of Dr Julian Chick as in-coming Chairman, effective 6th of May 2019, following the resignation of Mr Harvey Kaplan. Mr Kaplan was appointed in an interim capacity until a suitable Chair could be identified and has been pivotal in realigning the company and charting its path forward.

Rebuilding the foundation and recalibrating the strategic direction of the company over the past three months has required a considerable effort from the ShareRoot Board, lead by Mr Kaplan and newly appointed CEO, Michelle Gallaher.

Finding an appropriately qualified and experienced Chairman to advance the digital health focus of the company has been one of the organisations most important priorities.

Dr Julian Chick is an executive with more than 25 years of experience in the biotechnology and medical technology industry as well as five year in investment banking. Having led both public and private companies, Dr Chick's previous roles include investment adviser, healthcare analyst for private equity investors, portfolio manager, investment banker and venture capitalist.

Dr Chick has advanced a number of technologies from discovery through to market as well led numerous capital raisings, M&A transactions, company restructurings, business development and licensing transactions.

"I am excited to join the board of ShareRoot as the prospects of becoming a leader in the global digital health market are very exciting. The company has addressed its previous issues and is well on the way moving forward to becoming a successful business under Michelle Gallaher's guidance," stated Dr Julian Chick

Dr Chick has background with ShareRoot, as a shareholder and later working as an independent advisor on The Social Science transaction in April 2018 and more recently in the development of the Media Consent Medical functionality and market entry plan with Michelle Gallaher, ShareRoot CEO, over the past six months.

“We are really delighted and fortunate to welcome Dr Chick to the board,” said Michelle Gallaher. “Gaining access to Dr Chick’s investor network and know-how as well as his deep health technology development skills is a significant win for the company”.

“I’m grateful for Harvey Kaplan’s considerable support during this extraordinary period of transition,” said Michelle Gallaher. “Harvey has been very operational during the past three months, as have the whole board in stabilizing the business and helping me to reset the agenda.”

“I welcome Julian to the Chairmanship and look forward to seeing ShareRoot transform in the hands of an experienced leadership team with a clear vision for the company,” said outgoing Chairman Mr Harvey Kaplan.

“On behalf of the Board and management, I offer my thanks to Harvey for his professionalism and guidance and wish him well,” said Michelle Gallaher.

Pursuant to Listing Rule 3.16.4, the Company advises that the material terms of Dr Chick’s appointment are as follows:

- Director’s fee of \$40,000 per annum
- As part the appointment, subject to compliance with the Corporations Act and ASX Listing Rules. Dr Chick will be issued 11,000,000 unlisted and uninvested options, with each option exercisable at \$0.005 per option, expiring on the date 5 years from the date of issue. One third of the options will vest 1 year from the date of issue, a further one third of the options will vest 2 years from the date of issue, and the final one third of the options will vest 3 years from the date of issue.
- The term will commence 6 May 2019 and is initially for the period expiring at the next general meeting, at which time shareholders will consider Dr Chick’s re-election for a further period of up to 3 years.

End

For **investor** enquiries: Dr Julian Chick 0417 137 291

For **media** enquiries: Ms Laura Blue, Launch Link 0416 699 925 laura@launchlink.co